Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection

Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.

Publication Type:

Journal Article

Authors:

Thorpe, J.; Saeed, S.; Moodie, E.E.; Klein, M.B.

Source:

AIDS, Volume 25, Issue 7, p.967-975 (2011)

Keywords:

administration & dosage, Adult, Anti-Retroviral Agents, Antiretroviral, Antiretrovirals, Canada, CD4-Positive T-Lymphocytes, co-infected, co-infection, coinfection, complications, Disease, Disease Progression, drug therapy, etiology, Female, Fibrosis, HCV, Hepacivirus, Hepatitis C, Hiv, HIV Infections, Hiv-1, Humans, immunology, Interruption, Liver, Liver Cirrhosis, Male, Medicine, Middle Aged, Multicenter Studies, pathology, Patients, Research, Research Support, Risk, treatment, Victoria, Viral Load, Withholding Treatment

Cited On:

Patients With HIV/HCV Coinfection

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/21330904

Export Citation:

RIS Format

Top